FDA Grants Belgian Crohn’s Disease Candidate Orphan Designation

TiGenix’s candidate for a nasty Crohn’s disease complication received orphan drug designation after agreeing on a global Phase III trial.

TiGenix exploits the anti-inflammatory properties of donor-derived stem cells to treat diseases. One of its candidates, Cx601, is targeted at a complication of Crohn’s disease – a nasty inflammatory condition affecting the intestine. Cx601 met efficacy and safety endpoints during a European Phase III trial, prompting Japanese pharma giant, Takeda, to snap up its licensing rights for up to €380M. TiGenix will hope to repeat these findings in a larger study across Europe and North America. Having been awarded Orphan Designation by the FDA, the candidate’s journey to the US market should be accelerated.

Cx601 is a cell therapy for the treatment of complex perianal fistulas – a severe, debilitating complication of Crohn’s disease. Current treatment options include antibiotics, anti TNFs and surgery, but these have limited long-term efficacy and considerable safety concerns.

Boehringer Ingelheim is targeting Crohn’s disease – a market expected to be worth up to $4.2B (€3.6B) by 2022 – with its TNFɑ inhibitor, adalimumab biosimilar, Cyltezo, while TxCell is developing a T cell therapy for the condition. Also, keep an eye out for approaches using the microbiome like that of Enterome, which targets the FimH adhesin bacterial gene.


Images – BlurryMe / shutterstock.com

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.